Bolt Biotherapeutics, Inc. Common Stock BOLT
Analyst Ratings
- Consensus
- Buy — 2 Buy · 0 Hold · 0 Sell (2 analysts)
- Avg. Price Target
- $14.50 (+307.3% upside)
Key Stats
- Today's Range
- $3.10 – $3.62
- 50-Day Range
- $3.10 – $4.50
- 52-Week Range
- $3.10 – $7.20
- Volume
- 249K shs
- Average Volume
- 38K shs
- Market Cap
- $6.86 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 0.54
- Price / Sales
- 1.46
Short Interest
- Short Interest
- 22.62%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $4.70 million
- Net Income
- $-28,739,000
- Net Margin
- -611.47%
- Return on Equity
- -227.37%
- Debt-to-Equity
- —
About Bolt Biotherapeutics, Inc. Common Stock
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Related Stocks
Compare head-to-head: BOLT vs LLY·BOLT vs JNJ·BOLT vs ABBV·BOLT vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.